We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PASI 75 responses among patients treated with AX-158 ...

CUPERTINO, Calif., March 21, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a proof-of-concept trial with topical DUR-928 in ...

In September 2022, the US Food and Drug Administration (FDA) approved Sotyktu (deucravacitinib; Bristol-Myers Squibb Company), a tyrosine kinase 2 (TYK2) inhibitor, for the treatment of moderate to ...

A >500-patient, randomized, double-blind phase 3 trial showed CT-P43 achieved PASI 75 equivalence at week 12 versus ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Among ICP-488-treated patients, 77.3% to 78.6% achieved ...

Findings showed that 88.5% of patients achieved target lesion Physician Global Assessment success at week 12. Tapinarof cream was found to be an effective treatment for plaque psoriasis of the head ...

Despite recent significant advances in systemic therapies for psoriasis, topical treatment retains a prominent role for many patients. The American Academy of Dermatology/National Psoriasis Foundation ...

Red and near-infrared–emitting fabric clothing may improve symptoms of mild psoriasis, polymorphous light eruption (PMLE), and alopecia areata (AA), but further research with larger groups is needed ...

In its February 2024 meeting, the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use has granted marketing authorizations for Pyzchiva (ustekinumab) for the treatment ...

MARIETTA, Ga. - Greg Morrison of Marietta has been living with plaque psoriasis for more than 30 years. "The rash, it itches constantly," Morrison says. "It flakes. It kind of pinches you, and then ...